SCHEMBL10275585

SCHEMBL10275585

Cc1cccc(OCCCC=O)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 1/20 0.56
MAPT P10636 3/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
PPARG P37231 2/20 0.48
PPARD Q03181 2/20 0.48
PPARA Q07869 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 2/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
HTR1A P08908 2/20 0.45
ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27890770 0.91 HTR1B (0.62) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL10203537 0.83 TDP1 (0.42) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL5929458 0.81 HTR1B (0.71) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL15330864 0.80 HTR1B (0.51) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL10203531 0.79 CDK4 (0.48) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL4740590 0.78 HTR1B (0.62) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL10714769 0.78 HTR1B (0.50) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL30734669 0.78 HPGD (0.38) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL26635946 0.78 HPGD (0.38) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL30735422 0.78 HPGD (0.38) HTR1BMAPTKDM4EGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088936-B2 Leukotriene B4 inhibitors HOFFMAN-LA ROCHE INC. (US) 2012-01-03 US disclosed
US-7989454-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20100240678-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2010-09-23 US disclosed
US-20090253684-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253684-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S HTR1B 398/4885MAPT 4289/4885KDM4E 4057/4885
US-20100240678-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S HTR1B 391/4885MAPT 4334/4885KDM4E 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.